Goldman Sachs analyst Chris Shibutani maintains Amylyx Pharma (NASDAQ:AMLX) with a Neutral and raises the price target from $3 to $4.
Goldman Sachs Maintains Neutral on Amylyx Pharma, Raises Price Target to $4
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.